Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lentz

Showing results (61-70 of 106) with videos related to

Pageof 11
Sort By:
Gynecologic Oncology|February 22, 2005
Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group studyGregory Sutton, James Kauderer, Linda F Carson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group StudyS S Lentz, M F Brady, F J Major, et al.
Gynecologic Oncology|December 8, 2004
Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology GroupStephen D Williams, James Kauderer, Alexander F Burnett, et al.
Gynecologic Oncology|September 30, 1999
Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group studyJ S Berek, M Markman, B Stonebraker, et al.
Gynecologic Oncology|May 18, 1999
A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group StudyA Sedlis, B N Bundy, M Z Rotman, et al.
International Journal of Radiation Oncology, Biology, Physics|January 24, 2006
A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group studyMarvin Rotman, Alexander Sedlis, Marion R Piedmonte, et al.
ACS Infectious Diseases|September 1, 2020
Structural Basis for the Inhibitor and Substrate Specificity of the Unique Fph Serine Hydrolases of <i>Staphylococcus aureus</i>Matthias Fellner, Christian S Lentz, Sam A Jamieson, et al.
Gynecologic Oncology|September 9, 2022
HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patientsAnya V Menzies, Erik C Usher, Fang-Chi Hsu, et al.
American Journal of Obstetrics and Gynecology|June 15, 1983
Tubal microsurgery with the carbon dioxide laserJ A Fayez, V W Jobson, S S Lentz, et al.
Cancer Chemotherapy and Pharmacology|August 13, 2002
A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group studySteven C Plaxe, John A Blessing, George Olt, et al.
Pageof 11

Showing results (61-70 of 106) with videos related to

Sort By:
Pageof 11
Gynecologic Oncology|February 22, 2005
Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group studyGregory Sutton, James Kauderer, Linda F Carson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group StudyS S Lentz, M F Brady, F J Major, et al.
Gynecologic Oncology|December 8, 2004
Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology GroupStephen D Williams, James Kauderer, Alexander F Burnett, et al.
Gynecologic Oncology|September 30, 1999
Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group studyJ S Berek, M Markman, B Stonebraker, et al.
Gynecologic Oncology|May 18, 1999
A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group StudyA Sedlis, B N Bundy, M Z Rotman, et al.
International Journal of Radiation Oncology, Biology, Physics|January 24, 2006
A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group studyMarvin Rotman, Alexander Sedlis, Marion R Piedmonte, et al.
ACS Infectious Diseases|September 1, 2020
Structural Basis for the Inhibitor and Substrate Specificity of the Unique Fph Serine Hydrolases of <i>Staphylococcus aureus</i>Matthias Fellner, Christian S Lentz, Sam A Jamieson, et al.
Gynecologic Oncology|September 9, 2022
HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patientsAnya V Menzies, Erik C Usher, Fang-Chi Hsu, et al.
American Journal of Obstetrics and Gynecology|June 15, 1983
Tubal microsurgery with the carbon dioxide laserJ A Fayez, V W Jobson, S S Lentz, et al.
Cancer Chemotherapy and Pharmacology|August 13, 2002
A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group studySteven C Plaxe, John A Blessing, George Olt, et al.
Pageof 11